UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) September 16, 2024

 

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-50956

 

20-0653570

(State or other jurisdiction

of incorporation)

 

(Commission

 File Number)

 

(IRS Employer

Identification No.)

 

6 Road 696, Dorado, Puerto Rico

 

00646

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (787) 278-2709 

 

(Former name or former address, if changed since last report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

 

 

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On September 16, 2024, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release, dated September 16, 2024.

104

 

Cover page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PHARMA-BIO SERV, INC.

 

 

 

 

 

Date: September 16, 2024

By:  

/s/ Pedro J. Lasanta

 

 

 

Pedro J. Lasanta  

 

 

 

Chief Financial Officer, Vice President Finance and Administration and Secretary

 

 

 

3

 

nullv3.24.3
Cover
Sep. 16, 2024
Cover [Abstract]  
Entity Registrant Name Pharma-Bio Serv, Inc.
Entity Central Index Key 0001304161
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Sep. 16, 2024
Entity File Number 0-50956
Entity Incorporation State Country Code DE
Entity Tax Identification Number 20-0653570
Entity Address Address Line 1 6 Road 696
Entity Address City Or Town Dorado
Entity Address Postal Zip Code 00646
City Area Code 787
Local Phone Number 278-2709
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Address Country PR

Pharma Bio Serv (QB) (USOTC:PBSV)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Pharma Bio Serv (QB) Charts.
Pharma Bio Serv (QB) (USOTC:PBSV)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Pharma Bio Serv (QB) Charts.